NASDAQ:MLND Millendo Therapeutics (MLND) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free MLND Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.08▼$3.2850-Day Range$3.06▼$5.8452-Week Range$0.92▼$16.95Volume388,964 shsAverage Volume1.52 million shsMarket Capitalization$61.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Millendo Therapeutics alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Millendo Therapeutics Stock (NASDAQ:MLND)As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. MLND Stock News HeadlinesMarch 20, 2024 | msn.comA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 7, 2024 | msn.comMind Medicine sends psychedelic stocks higher after FDA status for LSD formulationApril 23, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.January 11, 2024 | markets.businessinsider.comClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementDecember 5, 2023 | msn.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?November 6, 2023 | markets.businessinsider.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)March 15, 2023 | benzinga.comExpert Ratings for Decibel TherapeuticsDecember 29, 2022 | insidermonkey.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call TranscriptApril 23, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.December 29, 2022 | yahoo.comClearmind Medicine Announces Shareholders Meeting ResultsJune 3, 2022 | finance.yahoo.comClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in IndiaMay 31, 2022 | finance.yahoo.comDTx Pharma Appoints Michael Huang, MD as Chief Medical OfficerMay 19, 2022 | finance.yahoo.comClearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol ConsumptionMay 16, 2022 | seekingalpha.comMind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call TranscriptMay 15, 2022 | finance.yahoo.comClearmind Announces Pre-IND Meeting Date with FDASee More Headlines Receive MLND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MLND CUSIPN/A CIKN/A Webwww.millendo.com Phone734 845 9000FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.03% Return on Assets-72.44% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book1.82Miscellaneous Outstanding Shares19,043,000Free FloatN/AMarket Cap$61.70 million OptionableNot Optionable Beta0.48 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key CompetitorsLantern PharmaNASDAQ:LTRNEquilliumNASDAQ:EQKronos BioNASDAQ:KRONMarinus PharmaceuticalsNASDAQ:MRNSEagle PharmaceuticalsNASDAQ:EGRXView All Competitors MLND Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX). This page (NASDAQ:MLND) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
